WCDA - PKPD Workshop

Tuesday,
September 07th, 2004

Wednesday,
September 08th, 2004

PK / PD General Concepts

Physiologically Based PK - Michael Weiss
Recirculatory modeling (initial distribution)
PK in isolated organs and destructive sampling
Allometric up-scaling

(Including general discussion)

PK / PD General Concepts

Clinical Pharmacology = Disease Progression + Drug Action
Nick Holford
Introduction to the concepts of disease progression modeling
Application to clinical pharmacology and drug development
Alzheimer's disease and Parkinson's disease

(Including general discussion)

Applications in Anticancer Drug Therapy

Charlotte Kloft, Berlin:
Pharmacokinetics of high-molecular anticancer agents

Ulrich Jaehde, Bonn:
Surrogate parameters in cancer chemotherapy

Rüdiger Port, Heidelberg:
Tissue pharmacokinetics with non-invasive measurements

Time	Topic
8:30	PK 1 Basic Principles - Michael Weiss Structure of the body, administration and sampling sites Transport processes Clearance, volume of distribution, half-life
9:30	PD 1 Ligand Binding and Receptors - Nick Holford Receptors and binding sites Specific binding and non-saturable binding Occupancy, stimulus and response models
10:30	Coffee
11:00	PK 2 Processes - Michael Weiss Hepatic and renal elimination Absorption and bioavailability Plasma protein and tissue binding
12:00	PD 2 Immediate Drug Effects - Nick Holford The E_max and Sigmoid E_max models of drug action Time course of drug effect Duration of drug effect
13:00	Lunch
14:00	PK 3 Data Analysis I - Michael Weiss Compartmental and noncompartmental models
14:45	Population Data Analysis - Nick Holford Individual vs population methods Why understanding fixed and random effects is important Sources of PK and PD variability
15:30	Coffee
16:00	Common Parallel Session – Discussion (PK and PD) Nick Holford & Michael Weiss
16:30	End

Time	Topic
	PK / PD General Concepts
8:30	Advanced PK 4 Michael Weiss Multiple dosing Designing dose regimens Nonlinear PK
9:30	PD 3 Delayed Drug Effects Nick Holford Distribution delay and the effect compartment Physiological delay and the turnover model family Thiopentone, digoxin, warfarin, anti-depressants
10:30	Coffee
11:00	Advanced PK 5 Data Analysis II Michael Weiss Oral administration Metabolite PK
12:00	PD 4 Exposure Response Nick Holford What does exposure mean? Cumulative effects and schedule dependence Diuretics and anti-cancer agents
13:00	Lunch

14:30 - 16:30	PK / PD General Concepts
	Physiologically Based PK - Michael Weiss Recirculatory modeling (initial distribution) PK in isolated organs and destructive sampling Allometric up-scaling (Including general discussion)
14:30 - 16:30	PK / PD General Concepts
	Clinical Pharmacology = Disease Progression + Drug Action Nick Holford Introduction to the concepts of disease progression modeling Application to clinical pharmacology and drug development Alzheimer's disease and Parkinson's disease (Including general discussion)

14:30 - 17:00	Applications in Anticancer Drug Therapy
	Charlotte Kloft, Berlin: Pharmacokinetics of high-molecular anticancer agents Ulrich Jaehde, Bonn: Surrogate parameters in cancer chemotherapy Rüdiger Port, Heidelberg: Tissue pharmacokinetics with non-invasive measurements